Aflibercept
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4086 publications
Visual Acuity and Durability Outcomes of Faricimab Compared With Other Anti-vascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Diabetic Macular Edema.
Journal: Journal of vitreoretinal diseases
Published: April 13, 2026
Hyperbaric Oxygen Therapy Combined With Intravitreal Aflibercept for Combined Retinal Vascular Occlusion in a Young Patient.
Journal: Journal of vitreoretinal diseases
Published: April 13, 2026
Visual Acuity and Durability Outcomes of Faricimab Compared With Other Antivascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Neovascular Age-Related Macular Degeneration.
Journal: Journal of vitreoretinal diseases
Published: April 13, 2026
Age-Specific Increases in the Prevalence and Treatment Burden of Neovascular Age-Related Macular Degeneration in a Super-Aged Society.
Journal: Investigative ophthalmology & visual science
Published: April 10, 2026
SDF-1 Inhibition Attenuates VEGF-Driven Retinal Leukostasis and Neovascularization in Ischemic Retinopathy.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Published: April 10, 2026
Dexamethasone implant and aflibercept combination therapy versus aflibercept monotherapy for diabetic macular edema: A prospective, comparative trial (COED trial).
Journal: Retina (Philadelphia, Pa.)
Published: April 09, 2026
Correction: Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials.
Journal: Ophthalmology and therapy
Published: April 04, 2026
Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience - the APEX study.
Journal: Expert opinion on biological therapy
Published: April 02, 2026
Bilateral Serous Maculopathy Associated with Acalabrutinib Therapy in Chronic Lymphocytic Leukemia.
Journal: Retinal cases & brief reports
Published: April 01, 2026
Efficacy and Safety of the Proposed Biosimilar Aflibercept, SDZ-AFL, in Patients With Neovascular Age-Related Macular Degeneration: 52-Week Results From the Phase 3 Mylight Study: Erratum.
Journal: Retina (Philadelphia, Pa.)
Published: March 31, 2026
Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction.
Journal: JAMA ophthalmology
Published: March 26, 2026
In brief: Aflibercept (Eylea HD) for macular edema following retinal vein occlusion.
Journal: The Medical letter on drugs and therapeutics
Published: March 24, 2026
Last Updated: 04/28/2026